Drugs / D6-25-hydroxyvitamin D3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03576716 | Jun 2018 → Jul 2019 | chronic kidney disease | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT03104855 | Apr 2017 → Oct 2018 | cystic fibrosis | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT02937350 | Mar 2017 → Jul 2019 | chronic kidney disease | University of Washington | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D6-25-hydroxyvitamin D3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576716 ↗ |
| Known as | d-25[OH]D3 | “We administered intravenous, deuterated 25(OH)D3 (d-25[OH]D3) in a pharmacokinetic study of 87 adults, including 43 with normal eGFR (≥60 ml/min per 1.73 m2), 24 with...” PMID 33115916 ↗ Oct 2020 |
| Route | Intravenous | “Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3” NCT02937350 ↗ |